Clinical Trial Update: WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 bioequivalence study comparing ganciclovir from valganciclovir syrup to Valcyte 450 mg tablet (900 mg total) in kidney transplant recipients; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Valcyte (valganciclovir)
• valganciclovir syrup (valganciclovir)

Snippet

Sponsor: University of Pittsburgh | Conditions: Kidney Transplant | Phase 3 | Status: TERMINATED